


Delaware Judge Denies Sarepta Protection Under Hatch-Waxman “Safe Harbor”

mRNA Patent and Competitive Landscape: 2021 Year in Review and 2022 Outlook

Three (3) Initial Considerations for Entrepreneurial Faculty, Researchers, Post-Docs, and Graduate Students

Alphabet Dives Further Into AI-Driven Drug Discovery

Next Up for BioNTech: Malaria

The mRNA Patent and Competitive Landscape: Pioneers, Litigation Outlook and Big Pharma’s Next Moves (Part III)

The mRNA Patent and Competitive Landscape: Translate BIO; Arcturus; eTheRNA and Other Startups; and LNP Technology (Part II)

The mRNA Patent and Competitive Landscape Through One Year of the COVID-19 Pandemic–Part I

IP Assignment Considerations for Emerging Companies
Subscribe: Subscribe via RSS
Blogs
Firm/Org